Benzenesulfonic Acid, Mono-C10-13-Alkyl Derivs., Compds. With Ethanolamine is a process solvent in pharmaceutical manufacturing whose residual presence in drug substances is controlled by ICH Q3C PDE-derived concentration limits. Its physicochemical properties—vapour pressure, water miscibility, and octanol-water partition coefficient—govern both its solvent utility in process chemistry and the efficiency of its removal during drying steps. The PDE for Benzenesulfonic Acid, Mono-C10-13-Alkyl Derivs., Compds. With Ethanolamine is calculated by dividing the critical study NOAEL by a composite uncertainty factor comprising F1 for interspecies extrapolation, F2 for intraspecies variability, and F3 for study duration adjustment relative to chronic exposure.
The pharmacologically-based OEL approach is used for Benzenesulfonic Acid, Mono-C10-13-Alkyl Derivs., Compds. With Ethanolamine when its receptor-mediated pharmacodynamic activity in humans produces the most sensitive adverse effect at doses below the NOAEL from general organ toxicity studies.
